Trial
NCT03193437
Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Georgetown University
Collaborators
Hackensack Meridian Health; Karyopharm Therapeutics Inc
Condition
Thymoma
Intervention
Open Label Selinexor
Why stopped
Slow Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-16